Table 1:
Study participant characteristics
| Controls | ALS | |||
|---|---|---|---|---|
| Baseline | Longitudinal | |||
| N | 21 | 46 | 29 | |
| Age at baseline, years | Mean ± SD (range) | 60.6 ± 6.9 (49-71) | 66.0 ± 11.7 (42-85) | 65.7 ± 12.9 (42-84) |
| Age at diagnosis, years | Mean ± SD (range) | -- | 66.1 ± 11.7 (42-85) | 64.4 ± 11.4 (42-84) |
| Sex, male | N (%) | 10 (48%) | 33 (72%) | 22 (76%) |
| Familial disease | N (%) | -- | 2 (4.3%) | 0 |
| Bulbar onset | N (%) | -- | 17 (36%) | 11 (38%) |
| Months from onset to diagnosis | Mean ± SD (range) | -- | 10.4 ± 8.1 (0.4-41) | 10.4 ± 8.9 (0.4-41) |
| Months from diagnosis to baseline | Mean ± SD (range) | -- | 5.2 ± 6.8 (0.3-37) | 5.27 ± 5.6 (0.5-21) |
| Baseline ALSFRS-R | Mean ± SD (range) | -- | 39.8 ± 4.6 (27-47) | 41.4 ± 3.9 (31-47) |
| Baseline ΔFRS | Mean ± SD (range) | -- | 0.68 ± 0.5 (0.02-2.7) | 0.54 ± 0.3 (0.02-1.17) |
| Death | N (%) | -- | 44 (96%) | 27 (93%) |
| Disease duration, months a | Median (IQR) | -- | 19.5 (11.34-38.6) | 22.14 (18.3-41.9) |
| Sampling time points | Median (range) | -- | -- | 3 (2-6) |
ΔFRS = estimated rate of progression (change in ALSFRS-R per month from onset of weakness to baseline)
IQR = interquartile range (25th-75th percentile)
a
From diagnosis to death